Avalo Therapeutics, Inc. (AVTX)
$13.65+1.64%Close
SELLCRISIS · day 22
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $154M
- Beta
- 0.79
- P/E (TTM)
- -2.87
- Short % float
- 105.23%
- Days to cover
- 8.8
- SI change
- -11.8%
- 1W
- -8.94%
- 1M
- -20.55%
- vs SPY 1W
- -10.10%
- vs SPY 1M
- -23.54%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 2
- GROWTH
- 4
- GARP
- 2
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-34.8%
REV YoY-
ROE-58.0%
EPS YoY-
ROA-20.4%
GROSS-16861
OP-154844
NET-170056
[VALUATION]
P/E TTM-2.87
P/E FWD-
SECTOR PE20.47
INDUSTRY PE13.95
P/B1.32
P/FCF-
EV/EBITDA-6.29
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E0.05
ALTMAN Z-
CURR RATIO19.31
ND/EBITDA-
BETA0.79
Company news
FAQ
- What is LOPJLB’s current signal on AVTX?
- LOPJLB’s latest quantitative signal on Avalo Therapeutics, Inc. (AVTX) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is AVTX in?
- Avalo Therapeutics, Inc. (AVTX) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Avalo Therapeutics, Inc. (AVTX) do?
- Avalo Therapeutics, Inc. is a precision medicine company in the clinical development phase, dedicated to identifying, advancing, and marketing specialized treatments for patients experiencing critical unmet medical needs across the fields of immunology, immuno-oncology, and rare genetic disorders. Among its key pipeline assets is AVTX-002, a fully human monoclonal antibody designed to inhibit L…